Literature DB >> 11040272

The status of high-dose chemotherapy in breast cancer.

S Rodenhuis1.   

Abstract

High-dose chemotherapy in breast cancer is a subject of considerable controversy. Preliminary results from several randomized trials have shown that it is certainly not the breakthrough hoped for in the early 1990s. The available data are, however, compatible with a modest but potentially important effect on relapse-free survival in the adjuvant treatment of high-risk breast cancer. To prove such an effect, several more years of maturation are required for a number of randomized studies. At this point in time, there is no justification for the use of high-dose chemotherapy in breast cancer outside clinical studies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11040272     DOI: 10.1634/theoncologist.5-5-369

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  6 in total

Review 1.  High-dose chemotherapy in breast cancer.

Authors:  Diana E Lake; Clifford A Hudis
Journal:  Drugs       Date:  2004       Impact factor: 9.546

2.  Toxicity of the high-dose chemotherapy CTC regimen (cyclophosphamide, thiotepa, carboplatin): the Netherlands Cancer Institute experience.

Authors:  J G Schrama; M J Holtkamp; J W Baars; J H Schornagel; S Rodenhuis
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

3.  Single oral dose acute and subacute toxicity of a c-MET tyrosine kinase inhibitor and CDK 4/6 inhibitor combination drug therapy.

Authors:  Brian Smith; Yi-Hsin Hsu; Rene Flores; Mihai Gagea; Suzanne Craig; Mien-Chie Hung
Journal:  Am J Cancer Res       Date:  2018-01-01       Impact factor: 6.166

Review 4.  The pro-tumorigenic host response to cancer therapies.

Authors:  Yuval Shaked
Journal:  Nat Rev Cancer       Date:  2019-10-23       Impact factor: 60.716

5.  Albumin-Gold Nanorod Nanoplatform for Cell-Mediated Tumoritropic Delivery with Homogenous ChemoDrug Distribution and Enhanced Retention Ability.

Authors:  Hsien-Ting Chiu; Cheng-Kuan Su; Yuh-Chang Sun; Chi-Shiun Chiang; Yu-Fen Huang
Journal:  Theranostics       Date:  2017-07-22       Impact factor: 11.556

6.  Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy.

Authors:  Marieke A Vollebergh; Esther H Lips; Petra M Nederlof; Lodewyk F A Wessels; Jelle Wesseling; Marc J Vd Vijver; Elisabeth G E de Vries; Harm van Tinteren; Jos Jonkers; Michael Hauptmann; Sjoerd Rodenhuis; Sabine C Linn
Journal:  Breast Cancer Res       Date:  2014-05-15       Impact factor: 6.466

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.